Probiotic spore‐based bioresponsive drug delivery for reversing inflammatory bowel disease and its associated anxiety and depression
Patients with inflammatory bowel disease (IBD) often exhibit gut microbiota dysbiosis and are predisposed to psychiatric disorders such as anxiety and depression. Consequently, developing novel oral probiotic therapies to address intestinal inflammation, microbiota dysbiosis, and psychiatric comorbidities is essent...